Background. End-stage renal failure (ESRF) patients demonstrate augmented growth hormone (GH) secretion, but normal insulin-like growth factor-I (IGF-I) concentrations, indicating a state of GH resistance. To test this hypothesis, we compared the IGF-I response with exogenous GH in haemodialysis patients and healthy controls, with special focus on free GH and bioactive IGF-I. Methods. Ultrafiltered free GH and total GH were measured in serum collected hourly for 24 h at baseline and after 7 days of recombinant human (rh) GH (50 µg/ kg/day) treatment in 11 non-diabetic haemodialysis patients and 10 matched controls. Serum levels of bioactive IGF-I (determined by cell-based IGF-I receptor activation assay), total IGF-I and the GH-binding protein (GHBP) were assayed twice daily. Results. At baseline, patients showed elevated total GH (24 ± 5 versus 9 ± 1 µg/L × h, P < 0.02), free GH (21 ± 5 versus 7 ± 1 µg/L × h, P < 0.02), reduced GHBP (1.5 ± 0.3 versus 2.5 ± 0.2 nmol/L, P < 0.01), high-normal total IGF-I (173 ± 18 versus 135 ± 14 µg/L, P = 0.12) and subnormal bioactive IGF-I (2.1 ± 0.3 versus 2.8 ± 0.2 µg/L, P < 0.05) when compared with controls. After 7 days of rhGH treatment, there was a greater GH increase in the non-diabetic haemodialysis patients than in controls (total GH: 293 ± 33 versus 166 ± 13 µg/L × h, P < 0.001; free GH: 284 ± 40 versus 126 ± 15 µg/L × h, P < 0.001). GHB remained unaffected and total IGF-I increased to the same extent in patients and controls (701 ± 87 versus 572 ± 33 µg/L, P = 0.17), whereas bioactive IGF-I tended to be lower in patients (5.37 ± 0.55 versus 6.63 ± 0.25 µg/L, P < 0.10). When adjusting for the actual increments in plasma GH, the ability of exogenous GH to stimulate bioactive IGF-I levels was reduced by ∼50% in ESRF (P < 0.02), whereas the response of total IGF-I remained normal (74%; P = 0.18) Conclusions. The study demonstrates that ESRF is associated with markedly elevated serum levels of free GH. Furthermore changes in bioactive, but not immunoreactive, IGF-I indicated that the hepatic sensitivity to GH was reduced by 50% in ESRF patients. Clearly, the physiological importance of our observations awaits further studies, but they suggest that changes in total IGF-I may not necessarily reflect changes in the endogenous activity of IGF-I in ESRF patients on GH treatment.
Introduction
Patients with end-stage renal failure (ESRF) are characterized by an amplified spontaneous and stimulated growth hormone (GH) secretion [1, 2] , and GH levels also reach higher values following subcutaneous (s.c.) and intravenous (i.v.) injection with recombinant human (rh) GH as compared with healthy subjects (HS) [1, 3] . These observations have been explained by a reduced metabolic clearance rate (MCR) of GH. In HS, the renal clearance of GH is virtually independent of plasma GH levels, whereas the extra-renal clearance (i.e. tissue uptake of GH) becomes saturated at relatively low GH levels. Accordingly, in ESRF patients the clearance of GH depends solely on the limited capacity of the tissues to metabolize GH [1, 4, 5] .
In addition to a reduced MCR of GH, ESRF is associated with low plasma levels of the high-affinity GHbinding protein (GHBP), which originates from enzymatic cleavage of the extracellular domain of the GH receptor (GHR) [3, 6] . GHBP circulates in molar excess of baseline GH levels, and therefore GHBP possesses a considerable binding capacity that is believed to dampen the fluctuations of plasma GH otherwise caused by its pulsatile secretion [7] . In ESRF, it seems inevitable that the combination of elevated GH and reduced GHBP will result in increased absolute as well as relative levels of 'free' GH [8] . However, this hypothesis remains to be confirmed by direct measurements of free GH.
Despite an amplified GH secretion levels of the GH-dependent peptide insulin-like growth factor-I (IGF-I) remain within the normal range, hereby supporting the concept that ESRF is characterized by GH resistance [9] . On the other hand, studies of serum from patients with ESRF have demonstrated that levels of intact as well as degraded IGF-binding proteins (IGFBPs) are highly elevated, most likely as a consequence of renal failure, and result in an inhibition of IGF-I action as estimated by in vitro bioassays [10] [11] [12] . In accordance with these findings, we have previously demonstrated that serum levels of free IGF-I are reduced and positively correlated to the glomerular filtration rate in patients with renal failure. Thus, it is likely that part of the GH hypersecretion in ESRF is caused by a reduced pituitary feedback inhibition by circulating-free IGF-I [12] .
The 'first aim' of this study was to test the hypothesis that patients with ESRF have elevated serum levels of 'free' GH, and for that purpose we compared 24-h profiles of free and total GH levels in HS and patients with ESRF before and after 7 days of s.c. treatment with GH, using a novel in-house ultrafiltration method which enables the assessment of serum-free GH under approached 'in vivolike' conditions [13] . The 'second aim' was to assess the impact of GH treatment on levels of bioactive IGF-I as estimated by a validated, highly specific cell-based IGF-I kinase receptor activation (KIRA) assay [14] . Since the binding capacity of IGF-I is markedly increased in the serum of ESRD patients [10, 11] , we hypothesized that GH induces a smaller relative increase in bioactive IGF-I when compared with total IGF-I.
Materials and methods

Study population
This study is an extension of a previously published investigation by Langbakke et al., describing changes in 24-h profiles of total GH levels and overnight fasting levels of immunoreactive (i.e. total) IGF-I, IGFBP-1 to -3 and GHBP in a cohort consisting of 11 non-diabetic, ESRF haemodialysis patients and 10 matched healthy controls [3] . In brief, patients with ESRF had been on haemodialysis between 0.3 and 6.7 years. Patients and controls were matched for fasting blood glucose levels (4.6 ± 0.5 versus 4.8 ± 0.5 mmol/L), age (51.3 ± 13.5 versus 50.2 ± 12.5 years), gender (females/males n: 3/8 versus 3/7), body mass index (25.0 ± 3.2 versus 26.3 ± 1.8 kg/m 2 ), race (all Caucasians) and systolic and diastolic blood pressures (data not shown).
The ESRF study group consisted of patients being on stable, chronic haemodialysis (defined as dialysis efficacy K t /V > 1.2 and/or a 4-h haemodialysis session performed 4 days a week) 3 months prior to enrolment. All study participants were free of active malignant disease, diabetes, critical illness, under treatment with glucocorticoids and immunosuppressive agents, active vasculitis, heart failure Class III to IV as defined by the New York Heart Association, severe hepatic disease and severe chronic inflammation [3] .
The study was performed at the APEX Research Centre in Munich, Germany in accordance with the Declaration of Helsinki and the International Conference on Harmonization Good Clinical Practice. The study was approved by the local Ethics Committee and all participants gave informed consent.
Study design
This was an open, non-randomized trial. Originally, one of the objectives of the present investigation was to study the safety aspects of GH in treating patients with ESRF. The presence of ESRF has been demonstrated to reduce the metabolic clearance of GH, and therefore the safety of GH treatment could be compromised by an accumulation of GH in the circulation [3] . For this reason, a supra-physiological dose of GH was chosen; all participants received a dose of 50 µg/kg of recombinant human (rh)-GH s.c. (Norditropin® SimpleXx®, Novo Nordisk A/S, Bagsvaerd, Denmark) with a maximum of 4 mg per day. In case of side effects, it was decided a priori to reduce the GH dose by 25% to 38 µg/ kg. Dose reduction was made in one patient at Day 5 (due to headache) and in another patient at Day 7 (due to one day of vomiting) [3] . As previously reported, this dose resulted in no accumulation of circulating GH in ESRF patients [3] .
GH was administered in the evening at 20.00 h, and each study period consisted of 24 h, starting with the injection of GH. ESRF patients were treated for 8 days and controls treated for 7 days. ESRF patients and controls were studied at baseline (before GH treatment was commenced), and at Day 7. In addition, ESRF patients were studied at Day 8. Patients were dialysed on alternate days (Days 2, 4, 6 and 8). Thus, the eighth study day included a haemodialysis session. One patient did not contribute to data on Day 8 because of a shunt obstruction. However, samples at baseline and Day 7 from this patient were included [3] .
Measurements
In the original study, samples were collected every 30 min for 24 h (20.00-20.00 h). However, free GH can only be assessed in undiluted serum [13] and as a result of a limited sample volume in each vial, samples were pooled on an hourly basis by combining similar volumes from samples obtained at each whole and half hour. Thus, in the present investigation, free and total GH levels were determined every hour. Free GH was isolated using ultrafiltration by centrifugation as previously described and validated by Frystyk et al. [13] . Unprocessed serum and ultrafiltrates were assayed for total GH and free GH, respectively, using the same commercial kit, specific for 22 kD GH (Delfia® hGH, Perkin Elmer Life Sciences, Turku, Finland). The GH kit was used as described by the manufacturer, except that all samples were incubated overnight rather than for 2 h. This modification was performed as it reduces the impact of GHBP on the antibody recognition of GH [15] .
For the measurements of IGF-I and GHBP, the 24-h profiles were pooled into a night sample (20.00-08.00 h) and a day sample (08.00-20.00 h). As stated above, care was taken to pool identical aliquots from all the samples. Serum levels of immunoreactive IGF-I (final dilution 1:1000) was determined in acid ethanol serum extracts using a validated, in-house time-resolved immunofluorometric assay (TR-IFMA) as previously described [16] . We have previously validated our IGF-I immunoassay in serum from patients with ESRF, and this validation showed that IGF-I levels obtained in acid ethanol extracted serum yielded similar levels as those obtained after fast liquid protein chromatography at low pH [17] . Serum levels of immunoreactive IGF-II (final dilution 1:1000) were determined by the TR-IFMA as previously described [16] with slight modifications: first, the IGF-II assay has been calibrated against the international IGF-II reference preparation WHO 96/538. Second, the detection antibody now consists of a goat polyclonal antibody (SigmaAldrich, catalogue No. I-7276; 2605 Brøndby, Denmark), which prior to use has been labelled with europium according to the manufacturer of the labelling kit (Perkin Elmer Life Sciences, Turku, Finland).
Bioactive IGF-I was measured by a KIRA assay based on human embryonic kidney cells transfected with the human IGF-I receptor [14] . In brief, diluted serum samples (1:10) were incubated with the transfected cells for 15 min at 37°C. Then samples were aspirated, cells lysed and the crude cell lysates assayed for levels of phosphorylated (i.e. activated) IGF-I receptors by a specific TR-IFMA as previously detailed [14] . The serum signals were compared with that of a serial dilution of rh-IGF-I. The KIRA is relatively specific for IGF-I (the cross reactivity of IGF-II and insulin equals 12% and <1%, respectively). GHBP levels were determined by an in-house immunoassay as previously described [18] . The coefficient of variations (CVs) for the assays were as follows (within assay and between assay CV): total GH, 5% and 5% [19] ; free GH, 7% and 11% [13] ; immunoreactive IGF-I and -II, 5% and 10% [16] , bioactive IGF-I, 10% and 15% [14] , GHBP, 4% and 12% [18] . Samples from a single participant were assayed in a single run.
Pharmacokinetic calculations
The pharmacokinetics of free and total GH were calculated on the basis of a two compartment model. The half-life was determined using linear regression analysis after in-transformation of raw data, and it was calculated as the ratio between In(2) and the slope of the regression line. The clearance was calculated as the ratio between the dose of GH administered and the area under the curve (AUC) of free or total GH.
Statistics
The AUC of free and total GH was calculated for all participants. The AUCs of controls and ESRF patients were compared at baseline and Day 7, respectively, by Student's unpaired t-test or Mann-Whitney's unpaired rank sum test, as appropriate. The AUCs of controls (baseline versus Day 7) were compared by the Student's paired t-test or the Wilcoxon paired rank sum test as appropriate. The AUCs of the ESRF patients (baseline versus Day 7 versus Day 8) were compared by one-way repeated measures ANOVA or by Friedman repeated measures ANOVA on ranks, as appropriate. For data based on two observations per 24-h profile (immunoreactive IGF-I and -II, bioactive IGF-I and GHBP, respectively), the means were calculated. Changes within controls (baseline versus Day 7) were compared by Student's paired t-test or the Wilcoxon paired rank sum test as appropriate. Changes within ESRF patients (baseline versus Day 7 versus Day 8) were compared by repeated measures ANOVA or by Friedman repeated measures ANOVA on ranks, as appropriate. The differences between the controls and ESRF patients at baseline and Day 7 were compared by Student's unpaired t-test or Mann-Whitney's unpaired rank sum test, as appropriate. The assessment of biological relationships was performed by Spearman rank order correlations. All data are given as arithmetic mean ± SEM. A P-value < 0.05 was considered statistically significant.
Results
Free GH, total GH and GHBP
The 24-h profiles of free GH, total GH and the fraction of free GH are shown in Figure 1 , whereas the corresponding integrated AUCs are shown in Table 1 .
At baseline, the AUCs of free GH and total GH were approximately 3-fold elevated in ESRF patients when compared with controls (P < 0.05). As a result of parallel elevations in free and total GH, the average 24-h fraction of free GH remained within the normal range in ESRF, despite lower levels of GHBP (P < 0.01).
Seven days of GH treatment increased the AUC of free GH more in patients than in controls (by 2.2-fold; P < 0.003). Similarly, the increase in total GH was more pronounced in ESRF patients than in controls (by 1.7-fold; P < 0.004). In both groups, levels of free GH peaked 5 h post-injection, but the relative levels of free GH were higher in ESRF patients than in controls: 108 ± 6 versus 81 ± 5% (P < 0.003). Overall, the average 24-h fraction of free GH was increased in ESRF patients only (P < 0.003), whereas it remained unchanged in controls. GHBP levels were unaffected by GH treatment in both the groups, remaining higher in controls than ESRF patients (P < 0.02).
To study the impact of haemodialysis per se on the 24-hour profiles of free and total GH, ESRF patients (n = 10) received an eighth GH injection in the evening of Day 8, prior to a scheduled haemodialysis session the following day. However, it appeared that neither the AUC of free GH, the AUC of total GH, nor the GHBP levels or the 24-h fraction of free GH were affected by haemodialysis when compared with the previous day when patients were free of haemodialysis (all P-values NS).
Total IGFs and bioactive IGF-I
The absolute levels at baseline and Day 7/8 are shown in Table 1 . Total and bioactive IGF-I as well as total IGF-II were measured in 12-h pooled samples, i.e. twice during each investigation. However, neither total IGF nor bioactive IGF-I showed any diurnal fluctuations and accordingly, we decided to use the mean level of the two samples. At baseline, levels of total IGF-I were numerically but not statistically elevated in ESRF patients when compared with controls (P = 0.12), whereas levels of bioactive IGF-I were significantly reduced (P < 0.05). Total IGF-II was statistically elevated in ESRF patients (P = 0.005).
GH treatment for 7 days increased total IGF-I to the same extent in ESRF patients and controls (P < 0.001). Thus, in regard to total IGF-I, the two groups showed similar increases (δ-values; P = 0.17) as well as absolute levels (P = 0.17) after 7 days of GH treatment. In ESRF patients, the increase in bioactive IGF-I was 87% of the increase observed in controls and this difference did not reach statistical significance. When comparing absolute levels of bioactive IGF-I after 7 days of GH treatment, levels tended to remain lower in ESRF patients when compared with healthy controls (P < 0.10). During GH treatment, serum total IGF-II changed neither in HS nor in ESRF patients.
The ability of exogenous GH to stimulate IGF-I (i.e. the IGF-I generation test) may be used to estimate the hepatic GH sensitivity [20] . As ESRF has been characterized by GH resistance [9] , we found it of interest to assess the hepatic IGF-I generating potential of exogenous GH, using the novel assays of free GH and bioactive IGF-I. More specifically, we calculated the ratio between the increases in IGF-I and GH, respectively, from baseline to Day 7. As shown in Table 2 , when the hepatic GH sensitivity was estimated on the basis of the measurements of total IGF-I and total GH, the hepatic GH sensitivity was numerically, but insignificantly lower in ESRF patients when compared with controls, and the same was true when using total IGF-I and free GH. By contrast, when estimated on the basis of bioactive IGF-I and either total or free GH, the hepatic GH sensitivity was significantly reduced in ESRF patients (P < 0.02).
Pharmacokinetic estimates of free and total GH
Calculations of GH pharmacokinetics were based on the assumptions of a two compartment system. However, the fast and slow half-lives of free GH were identical in ESRF patients (3.8 ± 0.5 versus 3.6 ± 0.4 h; P = 0.13) as well as in controls (5.5 ± 1.1 versus 5.4 ± 1.6 h; P = 0.31), and even though both half-lives were numerically shorter in ESRF patients than controls, the differences were insignificant (both P-values >0.30).
GH clearance was markedly lower in ESRF patients than in controls. This was true for free GH clearance (15.6 ± 2.3 versus 33.3 ± 3.8 L/min; P < 0.001) as well as total GH clearance (13.8 ± 1.4 versus 23.4 ± 1.6 L/min; P < 0.001). In ESRF patients, no difference between the clearance of free and total GH was observed (P = 0.13), whereas in controls the clearance of free GH was increased when compared with the clearance of total GH (P < 0.003).
Linear correlation analyses
Spearman rank order correlations based on the AUCs were used to assess possible biological relationships between the measured variables. Both at baseline and at Day 7, GHBP showed significant or borderline-significant inverse correlations with free GH and total GH, respectively (Table 3) , whereas free and total GH correlated positively (Table 2) . Neither total nor bioactive IGF-I showed any significant relationships with free GH, total GH or GHBP, and we also failed to observe any significant correlations between the two IGF-I measurements (data not shown).
Discussion
The present study aimed to compare 24-h serum levels of free and total GH in non-diabetic, haemodialyzed ESRF patients with healthy controls before and after 7 days of GH treatment. Furthermore, the impact of GH treatment on 24-h mean levels of bioactive IGF-I, total IGF-I, total Fig. 1 . The 24-h profiles in free GH (upper graphs), total GH (middle graphs) and the fraction of free to total GH (bottom graphs) before (graphs A-B-C) and after 7 days of rhGH treatment (graphs D-E-F) in HS (blue lines and circles) and ESRF patients (red circles and lines). The right-hand side graphs also illustrate changes in free GH, total GH and the ratio of free to total GH on Day 8 (black circles and lines) in ESRF patients. The ESRF patients were off haemodialysis on Day 7 and on haemodialysis on Day 8. However, no differences in the AUCs were observed. The AUCs of controls and ESRF patients were compared at baseline and at Day 7; the inserted P-values represent the statistical outcome of the unpaired statistical tests between the AUCs in the two groups. Please notice the different scales of the Y-axes on the graphs illustrating free and total GH. Data are expressed as mean and SEM.
IGF-II and GHBP was investigated. Prior to GH treatment, ESRF was associated with 3-fold elevated spontaneous 24-h serum profiles of free and total GH, normal and elevated levels of total IGF-I and total IGF-II, respectively, but reduced levels of bioactive IGF-I. Following GH treatment for 7 days, the increase in free and total GH levels were more pronounced in ESRF patients, in accordance with their subnormal GH clearance. Although ESRF patients are characterized by GH resistance, the achievement of higher free and total GH concentrations following GH treatment may explain that it was possible to increase bioactive and total IGF-I levels to the same extent as in HS. However, as indicated by the much higher increase in AUC of GH in ESRF patients, the ability of exogenous GH to generate IGF-I was reduced by on average 50% in ESRF. Finally, the acute impact of haemodialysis on circulating GH was investigated, revealing no effects on total GH, free GH or GHBP.
The present study is the first investigation aiming to directly assess 24-h levels of free GH in ESRF patients. This was achieved by employment of a recently developed and thoroughly validated ultrafiltration technique that allows free GH to be isolated in undiluted serum at 37°C [13] and as this is the first assay for free GH, there are no previous measurements available for comparison. Prior to GH treatment, ESRF patients demonstrated a 3-fold increase in spontaneous 24-h serum levels of free GH when compared with HS. This finding is in good accordance with expectations based on the observed increase in total GH and the concomitant suppression of GHBP in patients with ESRF. It is noteworthy that the overall elevation of 24-h levels of free and total GH in patients with ESRF appeared to be of similar relative magnitude (3.0 versus 2.7-fold, respectively), leaving the 24-h fraction of free GH within the upper normal range. We acknowledge that the latter finding may appear contradictive in light of higher total GH and lower GHBP levels in ESRF patients. However, it should be acknowledged that the spontaneous 24-h mean levels of GH never exceeded 2.2 µg/L (corresponding to 0.1 nmol/L), and accordingly on a molar basis GH levels remained much lower than those of GHBP (∼1.5 nmol/L) resulting in a surplus binding capacity of GHBP even in this situation. Thus, our findings confirm what has been suggested using different mathematical models--that GHBP is very potent in dampening the physiological oscillations in free GH levels [7, 21] .
Seven days of GH treatment with a daily dose of up to 4 mg resulted in approximately 2-fold higher increases in free and total GH levels in ESRF patients when compared with controls. The observation that there was a more pronounced increase in circulating total GH in ESRF than HS was in line with previous findings [1, 3, 4] , and it has now been documented that the same is true for free GH, which increased to a similar degree as total GH. Interestingly, only in ESRF an increased 24-h fraction of free GH could be detected following GH treatment; in HS the fraction remained in the range of 75% irrespective of GH Table 1 . A comparison of integrated, 24-h levels of free GH and total GH as well as mean 24-h levels of GHBP, total IGF-I, total IGF-II and bioactive IGF-I in the two study groups Free GH AUC (µg/L × h) 7 ± 1 21 ± 5 P < 0.04 126 ± 15* 284 ± 40* P < 0.003 302 ± 29 P = NS Total Free GH AUC (µg/L × h) 9 ± 1 24 ± 5 P < 0.03 166 ± 13* 293 ± 33* P < 0.004 319 ± 23 P = NS Free GH AUC (%) 77 ± 2 83 ± 5 P = NS 74 ± 4 94 ± 4* P < 0.003 85 ± 4 P = NS GHBP (nmol/L) 2.5 ± 0.2 1.5 ± 0.3 P < 0.01 2.4 ± 0.2 1.6 ± 0.3 P < 0.02 1.6 ± 0.2 P = NS Bioactive IGF-I (µg/L) 2.8 ± 0.2 2.1 ± 0.3 P < 0.05 6.6 ± 0.3* 5.4 ± 0.6* P < 0.10 5.6 ± 0.5 P = NS Immunoreactive IGF-I (µg/L) 135 ± 14 173 ± 18 P = NS 572 ± 33* 701 ± 87* P = NS 702 ± 95 P = NS Immunoreactive IGF-II (µg/L) 545 ± 25 710 ± 44 P = 0.005 538 ± 39 733 ± 46 P < 0.005 742 ± 53 P = NS HS were investigated before and after 7 days of rhGH treatment, whereas patients with ESRF were investigated at baseline, after 7 days of rhGH treatment (off haemodialysis), and after 8 days of rhGH treatment (on haemodialysis). As seen from the P-values, haemodialysis had no impact on GH, bioactive IGF-I, total IGF-I, total IGF-II or GHBP. Data are expressed as mean and SEM. *P < 0.005 when compared with baseline levels within the respective study group. GH sensitivity was estimated by calculating the increases (i.e. δ-values) in total IGF-I, bioactive IGF-I, free GH AUC and total GH AUC, respectively, for each subject following 7 days of rhGH treatment. Hereafter, for each subject the ratios between the various IGF-I and GH measurements were calculated, allowing the calculation of the group mean and SEM. Ratios in controls and patients were compared by the unpaired t-test or by Mann-Whitney rank sum test as appropriate. For clarity, the ratios including bioactive IGF-I have been multiplied by 100.
treatment. This emphasizes the prominent ability of GHBP to buffer levels of free GH, and also indicates that methods based on the calculation of the relative levels of free GH may be a relatively poor marker of changes in free GH. Serum GHBP has been suggested to reflect the hepatic GHR density, but human data to support this assumption are, however, sparse. Furthermore, studies in GH deficient patients with or without GH treatment as well as studies in acromegalic patients have failed to demonstrate consistent changes in serum GHBP [6] . Thus, it is not surprising that we observed no significant changes in serum GHBP either in HS or in ESRF patients following 7 days of GH treatment.
In the current study, GH was administered subcutaneously and data on free and total GH were based on samples pooled on an hourly basis. We were forced to choose this approach due to sample volume restrictions, but it has undoubtedly limited our ability to perform a thorough pharmacokinetic comparison of free and total GH. For example, in the original publication by Langbakke et al. [3] , employing 30 min sampling, the authors demonstrated a 30% reduction in the half-life of total GH in ESRF. By contrast, in the present study, the use of hourly collected samples may explain why we were unable to replicate a significant reduction in the half-life of total GH in ESRF patients, although values were in fact numerically lowered by 30%. On the other hand, we were able to demonstrate an ∼50% reduction in the clearance of free as well as total GH in ESRF, the latter being in line with previous findings in patients with ESRF [4] .
In HS, the clearance of free GH was some 50% higher than that of total GH, whereas in ESRF patients the clearance of free and total GH was comparable. However, one has to bear in mind that in ESRF the vast majority (∼95%) of the circulating GH pool was in fact free, and therefore, this observation was expected. The situation is different in HS, who had lower relative levels of free GH (∼75%) and accordingly a detectable difference in the clearance of free and total GH. Experimental data have shown that the GH: GHBP complex is cleared from the circulation in a 10-fold slower rate than free GH, partly because the complex is too large for glomerular filtration, partly because the complex has an impaired GHR uptake [5, 22] . Thus, the present demonstration of a higher clearance of free GH when compared with total GH was in agreement with expectations based on indirect evidence.
The second aim of our study was to compare the impact of GH treatment on changes in total IGFs and bioactive IGF-I as measured by an in-house KIRA assay based on cells transfected with the human IGF-I receptor [14] . The bioassay is unique in that it measures the ability of serum to stimulate (i.e. phosphorylate) the IGF-I receptor in vitro, hereby integrating into one measurement the contribution originating from free IGF-I, free IGF-II as well as IGFs loosely bound to degraded IGFBPs. Thus, the bioassay is distinctly different from the immunoassay, which determines IGF-I concentrations and neither takes into consideration the presence of the IGFBPs nor the contribution of IGF-II, which also acts on the IGF-I receptor. Furthermore, the bioassay appears to be of particular interest in ESRF, because this condition is characterized by an accumulation in plasma of intact and degraded IGFBPs. These changes ultimately reduce circulating levels of free as well as bioactive IGF-I while not affecting the total IGF-I and -II levels, which due to the elevated binding capacity remain within or above the normal range [10, 12, 17] . The present study confirmed our hypothesis, at least under the baseline conditions, where bioactive IGF-I was reduced by one-third in ESRF, despite high-normal levels of total IGF-I and elevated levels of total IGF-II, as previously observed [12] . However, following GH treatment levels of bioactive and immunoreactive IGF-I increased in parallel in patients and controls, albeit levels of bioactive IGF-I tended to be lower in ESRF (P < 0.10). By contrast, total IGF-I increased approximately 3-fold in both the groups. Therefore, we suggest that caution should be exercised when evaluating immunoreactive (total) IGF-I levels following GH therapy of ESRF patients.
It is well-established that ESRF associates with GH resistance, caused by reduced numbers of GHR on target tissues as well as an impaired intracellular JAK/STAT signalling [9] . We therefore found it of interest to estimate the degree of GH resistance in ESRF. To this end, we utilized the concomitant measurements of GH and IGF-I to generate an estimate of the hepatic GH sensitivity by Table 3 . Spearman rank order correlations at baseline (above the diagonal) and at Day 7 (below the diagonal)
Day 7 data
Baseline data versus total GH (r and P-values) versus free GH (r and P-values) versus GHBP (r and P-values) AUC of total GH All participants 0.98; P < 0.0001 −0.63; P < 0.003 Health subjects 0.95; P < 0.0001 −0.21; NS (P = 0.54) ESRF patients 0.99; P < 0.0001 −0.66; P < 0.04 AUC of free GH All participants 0.97; P < 0.0001 −0.70; P < 0.0005 Health subjects 0.93; P < 0.0001 −0.24; NS (P = 0.49) ESRF patients 0.90; P < 0.0001 −0.72; P < 0.02 GHBP All participants −0.76; P < 0.0001 −0.84; P < 0.0001 Health subjects −0.58; NS (P = 0.08) −0.72; P < 0.02 ESRF patients −0.69; P < 0.03 −0.88; P < 0.0001 comparing the increases (i.e. δ-values) in IGF-I levels and the increases in 24-h GH levels. When we related the increases in immunoreactive (total) IGF-I with those of either total or free 24-h GH, we found that the IGF-I generation was numerically, but insignificantly lowered to 58-74% in ESRF patients. By contrast, using bioactive IGF-I, the IGF-I generation potential was found to be significantly reduced to 45-56%, depending on whether we used the 24-h AUC of free or total GH. Thus, our data suggest that in ESRF patients on haemodialysis, the ability of GH to stimulate IGF-I action in vivo may be less pronounced than indicated by measuring changes in immunoreactive IGF-I. However, we acknowledge that this needs further confirmation. The study has some limitations that need to be considered. The present study was originally designed as a safety study of GH treatment in ESRF patients, aiming to clarify whether GH treatment resulted in an accumulation of circulating GH, and for this reason a supra-physiological dose of GH was chosen. No accumulation was observed as GH levels returned to baseline levels at the end of the 24-h study periods [3] . However, the high dose may have induced insulin resistance, which may have affected our results, as insulin is an important regulator of the IGF-system [23] . Unfortunately, we have no data allowing us to assess changes in insulin sensitivity during GH treatment. But in the original report, IGFBP-1 levels appeared to decrease after GH, indicating that GH treatment did induce some degree of hyperinsulinaemia [3] . Another study limitation was that, due to volume restrictions, we had to pool serum from the 24-h profiles into two samples (a day sample and a night sample) for the measurements of IGFs and GHBP. This necessity has no doubt hindered our ability to detect an effect of GH on IGF-I generation during the 24-h study periods. A third limitation is that although the two study groups were strictly age-matched, their age ranged from 24 to 66 years. The activity of the GH IGF-I axis shows a distinct agerelated decline [24] , and accordingly, from a physiological point of view, in elderly subjects the chosen GH dose is likely to be relatively higher than in younger subjects. However, the size of the two study groups precludes a detailed analysis of the effect of GH on different age groups.
In conclusion, we have for the first time determined free GH levels in patients with ESRF before and after GH treatment. Our data confirmed the assumption of markedly higher levels of free GH before as well as after GH treatment, and we also showed that the clearance of free GH was faster in HS than in ESRF patients, in accordance with their slower MCR. Finally, in ESRF patients exogenously administered GH appeared to stimulate bioactive IGF-I less efficiently that levels of immunoreactive IGF-I. Clearly, the physiological importance of these observations awaits further studies, but they suggest that changes in total IGF-I may not necessarily reflect changes in bioactive IGF-I in ESRF patients on GH treatment.
